Cixutumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade

Description of Cixutumumab Biosimilar - Anti-IGF1R, CD221 mAb - Research Grade

Introduction to Cixutumumab Biosimilar

Cixutumumab Biosimilar, also known as Anti-IGF1R, CD221 mAb – Research Grade, is a monoclonal antibody (mAb) that targets the insulin-like growth factor 1 receptor (IGF1R). It is a biosimilar version of the original drug, Cixutumumab, which was developed by ImClone Systems and Eli Lilly for the treatment of various types of cancer. Cixutumumab Biosimilar is produced by recombinant DNA technology and has shown promising results in preclinical studies for the treatment of cancer.

Structure of Cixutumumab Biosimilar

Cixutumumab Biosimilar is a fully human IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL) and one variable domain (VL). The variable domains of both the heavy and light chains contribute to the antigen-binding site, which is responsible for the specificity of the antibody.

Mechanism of Action

Cixutumumab Biosimilar acts by binding to the IGF1R, a transmembrane receptor that is overexpressed in many types of cancer. IGF1R is a key regulator of cell proliferation, survival, and differentiation, and its overexpression has been linked to tumor growth and metastasis. By binding to IGF1R, Cixutumumab Biosimilar inhibits the binding of insulin-like growth factor 1 (IGF1) and insulin-like growth factor 2 (IGF2), the ligands of IGF1R. This prevents the activation of downstream signaling pathways that promote cell growth and survival, ultimately leading to the inhibition of tumor growth.

Application of Cixutumumab Biosimilar

Cixutumumab Biosimilar has shown potential as a therapeutic agent for the treatment of various types of cancer, including breast, lung, colorectal, and pancreatic cancer. Preclinical studies have demonstrated its efficacy in inhibiting tumor growth and metastasis in animal models. In addition, Cixutumumab Biosimilar has been shown to enhance the efficacy of other cancer treatments, such as chemotherapy and radiation therapy, when used in combination.

Breast Cancer Breast

cancer is the most common type of cancer in women, and IGF1R is known to be overexpressed in a significant proportion of breast tumors. Studies have shown that Cixutumumab Biosimilar can effectively inhibit the growth of breast cancer cells in vitro and in vivo. It has also been shown to enhance the efficacy of chemotherapy drugs, such as paclitaxel and doxorubicin, in breast cancer treatment.

Lung Cancer Lung

cancer is a leading cause of cancer-related deaths worldwide, and IGF1R has been found to be overexpressed in a majority of lung cancer cases. Preclinical studies have shown that Cixutumumab Biosimilar can inhibit the growth and metastasis of lung cancer cells, and has also been shown to enhance the efficacy of chemotherapy drugs, such as cisplatin and gemcitabine, in lung cancer treatment.

Colorectal Cancer Colorectal

cancer is the third most common type of cancer and the second leading cause of cancer-related deaths worldwide. IGF1R has been found to be overexpressed in colorectal cancer cells, and studies have shown that Cixutumumab Biosimilar can inhibit their growth and induce cell death. It has also been shown to enhance the efficacy of chemotherapy drugs, such as 5-fluorouracil and oxaliplatin, in colorectal cancer treatment.

Cixutumumab Biosimilar - Anti-IGF1R, CD221 mAb binds to IGF1R recombinant protein in indirect ELISA Assay

Immobilized IGF1R recombinant protein (cat. No.PX-P5185) at 0.5µg/mL (100µL/well) can bind to Cixutumumab Biosimilar - Anti-IGF1R, CD221 mAb (cat. No.PX-TA1205) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450